In Vitro Combination Effect of Topical and Oral Anti-Onychomycosis Drugs on Trichophyton rubrum and Trichophyton interdigitale
- PMID: 33809181
- PMCID: PMC7999459
- DOI: 10.3390/jof7030208
In Vitro Combination Effect of Topical and Oral Anti-Onychomycosis Drugs on Trichophyton rubrum and Trichophyton interdigitale
Abstract
To evaluate the combination effects of anti-onychomycosis drugs, the minimum inhibitory concentrations of topical (efinaconazole, luliconazole, and tavaborole) and oral (itraconazole and terbinafine) drugs for Trichophyton rubrum and Trichophyton interdigitale (8 each, with a total of 16 strains) were determined using the microdilution checkerboard technique based on the Clinical and Laboratory Standard Institute guidelines. No antagonism was observed between the topical and oral drugs against all the tested strains. Efinaconazole with terbinafine exerted a synergistic effect on 43.8% of the strains tested (7/16 strains) and efinaconazole with itraconazole on 12.5% (2/16 strains). Conversely, luliconazole showed no synergistic effect with terbinafine but was synergistically effective with itraconazole against 31.3% of the strains (5/16 strains). Tavaborole showed no synergistic effect with terbinafine and was synergistically effective with itraconazole against 18.8% of the strains (3/16 strains). The results suggest that a combination of topical and oral drugs could be a potential clinical option for onychomycosis treatment, and overall, the efinaconazole and oral drug combination would be the most advantageous among the tested combinations.
Keywords: FIC index; anti-onychomycosis drug; combination antifungal effect.
Conflict of interest statement
The authors are the employees and stockholders of Kaken Pharmaceutical Co., Ltd. Kaken Pharmaceutical Co., Ltd. discovered Clenafin/Jublia, a topical onychomycosis treatment product that contains efinaconazole. Jublia is commercialized in the United States and Canada by Bausch Health Companies Inc.
Figures
Similar articles
-
Emerging Antifungal-Resistant Onychomycosis in a Dermatology Clinic in Kumamoto, Japan.Med Mycol J. 2025;66(2):61-67. doi: 10.3314/mmj.24-00028. Med Mycol J. 2025. PMID: 40451890
-
Efinaconazole 10% and Tavaborole 5% Penetrate Across Poly-ureaurethane 16%: Results of In Vitro Release Testing and Clinical Implications of Onychodystrophy in Onychomycosis.J Drugs Dermatol. 2016 Sep 1;15(9):1116-20. J Drugs Dermatol. 2016. PMID: 27602975
-
In vitro antifungal oral drug and drug-combination activity against onychomycosis causative dermatophytes.Med Mycol. 2006 Jun;44(4):357-62. doi: 10.1080/13693780500536893. Med Mycol. 2006. PMID: 16772230
-
Treatment of onychomycosis in an era of antifungal resistance: Role for antifungal stewardship and topical antifungal agents.Mycoses. 2024 Jan;67(1):e13683. doi: 10.1111/myc.13683. Mycoses. 2024. PMID: 38214375 Review.
-
Efinaconazole and Tavaborole.J Pharm Pract. 2017 Apr;30(2):245-255. doi: 10.1177/0897190016630904. Epub 2016 Jul 8. J Pharm Pract. 2017. PMID: 26873506 Review.
Cited by
-
Topical efinaconazole: A sequential combination therapy with oral terbinafine for refractory tinea unguium.J Dermatol. 2021 Sep;48(9):1401-1404. doi: 10.1111/1346-8138.15973. Epub 2021 May 24. J Dermatol. 2021. PMID: 34028842 Free PMC article.
-
Transungual Penetration and Antifungal Activity of Prescription and Over-the-Counter Topical Antifungals: Ex Vivo Comparison.Dermatol Ther (Heidelb). 2024 Sep;14(9):2495-2507. doi: 10.1007/s13555-024-01237-6. Epub 2024 Aug 12. Dermatol Ther (Heidelb). 2024. PMID: 39133361 Free PMC article.
-
Antifungal Combinations in Dermatophytes.J Fungi (Basel). 2021 Sep 5;7(9):727. doi: 10.3390/jof7090727. J Fungi (Basel). 2021. PMID: 34575765 Free PMC article. Review.
-
In Vitro Antifungal Combination of Terbinafine with Itraconazole against Isolates of Trichophyton Species.Antimicrob Agents Chemother. 2022 Jan 18;66(1):e0144921. doi: 10.1128/AAC.01449-21. Epub 2021 Oct 11. Antimicrob Agents Chemother. 2022. PMID: 34633845 Free PMC article.
References
-
- Baker S.J., Hui X., Maibach H.I. Progress on new therapeutics for fungal nail infections. Annu. Rep. Med. Chem. 2005;40:323–335.
LinkOut - more resources
Full Text Sources
Other Literature Sources